P28R: A Novel Immuno-oncology

Immuno-oncology concept

  • Empowers the immune system to fight against cancer
  • Drug Candidate P28R targets solid tumors
  • Shows a positive safety profile
  • Animal data indicates functionality with check point inhibitors
  • Has been tested in humans

Unmet medical needs

  • Primary focus on Head and Neck squamous cell carcinoma
  • Compelling in vivo animal studies and First-In-Man data
  • Significant market opportunity for orphan indication status